Mammalian TLRs comprise of at least 11 members, which are categorically divided into 2 membrane receptor groups. [3] The TLRs associated with the cell surface are TLR1, TLR2, TLR4, TLR5, TLR6, TLR10, TLR11, TLR12, and TLR13, whereas the TLRs associated primarily with endosomal membranes are TLR3, TLR7, TLR8, and TLR9. Phylogenetically, TLRs are generally divided into 6 families-TLR1, TLR3, TLR4, TLR5, TLR7, and TLR11. [4] Different TLRs recognize different microbial products i.e. TLRs are differentially activated by various types of PAMPs such as bacterial DNA, LPS, peptidoglycan, teichoic acids, fl agellin, pillin, viral dsRNA, and fungi zymosan.
Activated TLRs differentially trigger the expression of cytokines like the interferons, the interleukins-IL2, IL6, IL8, IL12, IL16, and TNF-. Binding of adaptor proteins to the TIR domain of TLRs trigger the downstream signaling cascade, leading to the activation of different transcription factors. [5, 6] Flagellin is recognized by TLR5. The TLR family members thus recognize specifi c patterns of microbial components. [3] 
Role of Toll-like receptors in Innate and Acquired Immunity
TLRs are the key initiators of innate and adaptive immune response due to high production of proinfl ammatory cytokines and chemokines, upregulation of co-stimulatory molecules, and activation of antigen presentation. TLR recognition of pathogens leads to expression of genes such as infl ammatory cytokines and co-stimulatory molecules. Antigen-specifi c acquired immunity developed due to phagocytosis-mediated antigen presentation together with TLR-dependent gene expression of infl ammatory cytokines and co-stimulatory molecules. [5, 6] In human naïve B cells, most of the 
Toll-like receptors and Autoimmunity
The roles of TLRs in development of autoimmune diseases have been studied recently. Autoreactive B cells are present in the lymphoid tissues of healthy individuals, but since they are subject to self-tolerance mechanisms, they remain silent. However, when tolerance to self-antigens fails, a complex of selfreactive antibodies against self-or cross-reactive DNA co-engages the antigen receptor and the TLRs, leading to a continuous activation of these auto-reactive B cells and the development of autoimmune diseases.
The maturation of antigen-presenting cells (APCs), in response to signals received by innate immune system, may lead to the breakdown of tolerance. This process is mainly activated by TLRs that have been triggered by self-antigens. [8] High absence of treg functions. [2] In autoimmunity, self antigens cannot be easily eliminated because of its excess number or is ubiquitous. [9] Many microbial infections have been found to be associated with development of autoimmune diseases. TLR ligand binds to their specifi c microbial products and to the Dendritic Cells (DCs) which further activate them and thus induce signals for maturation towards tolerogenic type. Autoreactive T cells develop when these DCs are exposed to microbial ligands. These developments of autoreactive T cells and the suppression of Tregs cells result in the breakdown of tolerance.
Thus, a set of events that follow activation through TLR results in the production of autoantibodies and cytokine response leads to autoimmune diseases. leads to the activation of autoreactive B cells. [10] TLR 3, 9 and 7 induces the production of IFN-a, Viral dsRNA binds to TLR 3 and activates NF-B which helps in the induction for formation of apoptotic bodies that further promote pDCs to produce IFN-. [11] Despite of many potential mechanisms for triggering of autoantibody production by microorganisms, it is It is also possible that an exacerbated response to pathogens initiated by TLR2 and TLR4 may potentiate SLE attacks. [12] TLR9 was originally identifi ed as a and TLR7 defi ciency can also infl uence autoantibody production. [11] Ehlers et al. [18] At present, the effi cacies of potential TLR7 and TLR9
inhibitors have been tried. They are mainly anti-malarial agents and inhibitory oligonucleotides. Anti-malarial agents have been used to treat SLE for more than a century, and hydroxychloroquine (plaquenil) is still considered to be an effective treatment for cutaneous SLE and for SLE-associated polyarthralgia, pleuritis, and pericarditis. [11] The potential for therapeutic development of TLR antagonists is also considered. Several biotechnology and pharmaceutical companies have programs to develop new drugs like agonists of TLRs to enhance immune responses against tumors and infectious agents or to correct allergic responses; or antagonists designed to reduce infl ammation due to infection or autoimmune disease. [19] The potent immunogenicity of lipopeptides is due to their ability to activate DCs by targeting and signaling through TLR-2. In addition, the simplicity and fl exibility in their design makes TLR antagonists highly attractive vaccine candidates for humans and animals. [20] TLRs represent attractive drug targets for modulation of immune response and hold promising applications for the treatment of infection and infl ammation. Two main strategies for targeting TLRs seem to be promising for drug development such as targeting TLRs with synthetic agonists or antagonists and targeting the protein-protein interaction involved in the TLR-activated signaling cascade.
Specifi cally, blockade of TIR/TIR interaction between TLRs and adapter proteins by low molecular weight is particularly encouraging for the development of orally-available agents. To address the need for additional and potentially superior vaccine adjuvants, a number of TLR agonists are currently being tested. While LPS is fairly toxic in humans, monophosphoryl lipid (MPL), another TLR4 ligand with a greatly improved safety profi le, has recently won approval for use as an adjuvant. [21] Finally, with the rapid progress in the development of therapeutic agonists for the TLRs, there is accompanying attention to, the theoretical possibility that such therapy may induce autoimmunity or autoimmune diseases. [22] TLR3 ligands have been identifi ed in the synovial fl uid of patients with RA, and TLR9 ligands have been found in the immune complexes of SLE patients.
Such observations raise concerns that pharmacological doses of TLR agonists could precipitate autoimmunity.
These considerations have also prompted interest in the potential of TLR antagonists, as therapeutic agents for autoimmune diseases in near future.
